3-(Azetidin-3-yl)-1H-indole | 1368911-80-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(Azetidin-3-yl)-1H-indole
• 英文别名: 3-(azetidin-3-yl)-1H-indole
• CAS: 1368911-80-1
• 化学式: C₁₁H₁₂N₂
• 分子量: 172.23
• InChiKey: MKTVSXQMFHOMLJ-UHFFFAOYSA-N

物化性质

• 沸点：
  373.7±22.0 °C(Predicted)
• 密度：
  1.199±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 3-(Azetidin-3-yl)-1H-indole 在 sodium cyanoborohydride 作用下， 生成 3-(1-methylazetidin-3-yl)-1H-indole
  参考文献：
  名称：

  WO2022/232233

  摘要：

  公开号：
• 作为产物：
  描述：

  在 盐酸 作用下， 以 水 为溶剂， 生成 3-(Azetidin-3-yl)-1H-indole
  参考文献：
  名称：

  WO2022/232233

  摘要：

  公开号：

文献信息

• [EN] PHARMACEUTICAL COMPOUND<br/>[FR] COMPOSÉ PHARMACEUTIQUE
  申请人：IOMET PHARMA LTD

  公开号：WO2015082499A2

  公开（公告）日：2015-06-11

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X2, X4, X10, and X11 may be the same or different and each is independently selected from C and N; X1, X3, X5, X6, X7, X8, and X9 may be the same or different and each is independently selected from C, N and O; each bond having a dotted line may independently be a double bond or a single bond, provided that valencies at each atom are maintained; the dotted lines joining X4 with the carbon atoms either side of X2 are single bonds, and are only present when X2 is absent, X3 is absent and X4 is C, and when these bonds are present the ring carbons on each side of X2 are not directly bonded to each other; each R1 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of R1 groups present is such that the valency of X1 is maintained; each R12, R13, R13', R14, R15 and R15 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valency of the ring carbon atoms is maintained; R16 may be present or absent and is selected from H and a substituted or unsubstituted organic group, provided that the number of R16 groups present is such that the valency of X2 is maintained; each R17 may be present or absent and may be the same or different and is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R17 groups present is such that the valency of X3 is maintained; each R2, R3, R4, and R5 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X6, X7, X8, and X9 are maintained; each R7, R8 and R9 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X10, X11, and X5 are maintained; and R6 is selected from H and a substituted or unsubstituted organic group, preferably H and a substituted or unsubstituted C1-C6 alkyl group; and wherein any R group may form a ring with any other R group on an adjacent and/or proximal atom.
• [EN] INDOLEAZETIDINES AND THEIR USE IN METHODS FOR TREATING 5-HT2 RESPONSIVE CONDITIONS<br/>[FR] INDOLEAZÉTIDINES ET LEUR UTILISATION DANS DES PROCÉDÉS DE TRAITEMENT D'ÉTATS SENSIBLES À 5-HT2
  申请人：[en]ELEUSIS THERAPEUTICS US, INC.

  公开号：WO2022232233A1

  公开（公告）日：2022-11-03

  The invention features compounds and pharmaceutical compositions useful for treating 5-HT2 responsive conditions. Also provided are methods of using the compounds or compositions of the invention for treating 5-HT2 responsive conditions in a subject in need thereof.
• WO2022/232233
  申请人：——

  公开号：——

  公开（公告）日：——